Detailed Coverage

Relic Technologies Reports FY26 Standalone Profit Amidst Consolidated Loss

Relic Technologies Ltd. has announced its financial results for the fiscal year ending March 31, 2026. The company reported a standalone net profit of ₹0.54 crore (₹54.20 lakh), a significant turnaround from a standalone net loss of ₹1.72 crore (₹171.87 lakh) in the previous fiscal year. This positive standalone performance was supported by standalone other income amounting to ₹1.30 crore (₹130.18 lakh).

Conversely, the consolidated financial performance presented a net loss of ₹6.94 crore (₹694.49 lakh) for FY26. This marks a widening of the consolidated net loss from ₹1.49 crore (₹148.74 lakh) reported in the prior financial year. Consolidated other income stood at ₹0.74 crore (₹74.37 lakh).

Reader Takeaway: Standalone profit turnaround; Consolidated loss widens amidst business pivot.

What just happened

Relic Technologies Ltd. has declared its financial results for the fiscal year 2025-26. The company achieved a standalone net profit of ₹0.54 crore, a positive shift from the prior year's loss. However, on a consolidated basis, the company's net loss increased to ₹6.94 crore.

Why this matters

The results indicate a mixed performance. While the standalone entity is showing signs of recovery, the overall consolidated picture reflects ongoing challenges and investments in its new business direction. The nil revenue from operations highlights the early stage of its business transition.

The backstory

Relic Technologies is undergoing a strategic pivot towards the pharmaceutical and wellness sector. This transition phase has involved board restructuring, including the appointment of Mr. Sachin Srivastava as CEO and Whole Time Director, and Ms. Radhika Shriram as a Director. The company also approved an 'Employee Stock Option 2025' plan for up to 1.10 lakh shares (1.97% of paid-up capital) to retain talent and implemented preferential share and warrant allotments during the year.

What changes now

With the new strategic direction towards pharmaceuticals and wellness, the company's focus will be on generating operational revenue from these new ventures. The board's reconstitution and the ESOP plan signal an effort to professionalize management and align employee incentives with growth.

Risks to watch

The primary risks include the continued absence of operational revenue, the significant widening of the consolidated loss, and the execution challenges in establishing a presence in the competitive pharmaceutical and wellness markets.

Peer comparison

(Data not available in the filing to provide peer comparison.)

Context metrics (time-bound)

• Standalone Net Profit (FY26): ₹0.54 crore (₹54.20 lakh)
• Standalone Net Profit (FY25): ₹(1.72) crore (₹(171.87) lakh)
• Consolidated Net Loss (FY26): ₹6.94 crore (₹694.49 lakh)
• Consolidated Net Loss (FY25): ₹1.49 crore (₹148.74 lakh)
• Standalone Other Income (FY26): ₹1.30 crore (₹130.18 lakh)
• Revenue from operations (Standalone FY26): Nil

What to track next

Investors should monitor the company's progress in generating revenue from its pharmaceutical and wellness ventures, the trend of its consolidated losses, and the impact of its strategic initiatives on profitability.